Table 2.
Cox univariable and multivariable analysis of PFI in prostate cancer patients.
| Total (n) | Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| T stage (T3&T4 vs. T2) | 492 | 3.785 (2.140-6.693) | <0.001 | 1.473 (0.710-3.059) | 0.299 |
| N stage (N1 vs. N0) | 426 | 1.946 (1.202-3.150) | 0.007 | 0.861 (0.500-1.483) | 0.589 |
| M stage (M1 vs. M0) | 458 | 3.566 (0.494-25.753) | 0.208 | ||
| Primary therapy outcome (PD&SD&PR vs. CR) | 438 | 6.627 (4.337-10.126) | <0.001 | 3.576 (2.054-6.226) | <0.001 |
| Race (Asian & Black or African American vs. White) | 484 | 0.751 (0.417-1.352) | 0.339 | ||
| Age (>60 vs. ≤60) | 499 | 1.302 (0.863-1.963) | 0.208 | ||
| Residual tumor (R1&R2 vs. R0) | 468 | 2.365 (1.566-3.570) | <0.001 | 1.017 (0.598-1.728) | 0.951 |
| PSA (ng/ml) (≥4 vs. <4) | 442 | 4.196 (2.095-8.405) | <0.001 | 1.650 (0.743-3.667) | 0.219 |
| Gleason score (8-10 vs. 6-7) | 499 | 4.675 (2.957-7.391) | <0.001 | 2.901 (1.603-5.253) | <0.001 |
CI: confidence interval; PSA: prostate-specific antigen.